Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01031758 · ClinicalTrials.gov registry record · NA
Reverse Cholesterol Transport (RCT) Study
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT01031758: Completed NA study, sponsored by University of Pennsylvania.
NCT01031758 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01031758, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the use of radiolabeled particulate cholesterol administered intravenously in association with albumin, as a method to study reverse cholesterol transport (RCT) in humans by analyzing changes in the tracer activity in total plasma, lipoproteins and feces.
Interventions
- OTHER 3H-Cholesterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01031758
The ClinicalTrials.gov registry entry for NCT01031758 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 3H-Cholesterol is the first listed.
NCT01031758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01031758 about?
NCT01031758 is a clinical study titled "Reverse Cholesterol Transport (RCT) Study". The purpose of this study is to investigate the use of radiolabeled particulate cholesterol administered intravenously in association with albumin, as a method to study reverse cholesterol transport (RCT) in humans by analyzing changes in the tracer activity in total plasma, lipoproteins and feces.
What is the current status of trial NCT01031758?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2009-11. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01031758?
The interventions under investigation include: 3H-Cholesterol (OTHER).
Who is sponsoring clinical trial NCT01031758?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.